MX393640B - Tratamientos antivirales intravenosos. - Google Patents

Tratamientos antivirales intravenosos.

Info

Publication number
MX393640B
MX393640B MX2020002008A MX2020002008A MX393640B MX 393640 B MX393640 B MX 393640B MX 2020002008 A MX2020002008 A MX 2020002008A MX 2020002008 A MX2020002008 A MX 2020002008A MX 393640 B MX393640 B MX 393640B
Authority
MX
Mexico
Prior art keywords
antiviral treatments
intravenous
intravenous antiviral
treatments
kits
Prior art date
Application number
MX2020002008A
Other languages
English (en)
Spanish (es)
Other versions
MX2020002008A (es
Inventor
Arnold Shane
John Michael Kilpatrick
Pooran Chand
Shanta Bantia
Yarlagadda Sudhakara Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX393640(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MX2020002008A publication Critical patent/MX2020002008A/es
Publication of MX393640B publication Critical patent/MX393640B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2020002008A 2006-02-13 2007-02-12 Tratamientos antivirales intravenosos. MX393640B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
PCT/US2006/013535 WO2007117241A1 (en) 2006-04-12 2006-04-12 Intramuscular antiviral treatments
PCT/US2007/003755 WO2007095218A1 (en) 2006-02-13 2007-02-12 Intravenous antiviral treatments

Publications (2)

Publication Number Publication Date
MX2020002008A MX2020002008A (es) 2020-07-13
MX393640B true MX393640B (es) 2025-03-21

Family

ID=38169715

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002008A MX393640B (es) 2006-02-13 2007-02-12 Tratamientos antivirales intravenosos.
MX2008010394A MX2008010394A (es) 2006-02-13 2007-02-12 Tratamientos antivirales intravenosos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2008010394A MX2008010394A (es) 2006-02-13 2007-02-12 Tratamientos antivirales intravenosos.

Country Status (11)

Country Link
EP (1) EP1986626A1 (enExample)
JP (3) JP2009538822A (enExample)
KR (9) KR102323339B1 (enExample)
AU (2) AU2007215156A1 (enExample)
BR (1) BRPI0707769A2 (enExample)
CA (1) CA2642260C (enExample)
EA (1) EA025483B1 (enExample)
HK (1) HK1212250A1 (enExample)
MX (2) MX393640B (enExample)
MY (1) MY166063A (enExample)
WO (1) WO2007095218A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102323339B1 (ko) * 2006-02-13 2021-11-08 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료
CN101367750B (zh) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko) 2020-09-07 2022-03-17 주식회사 경보제약 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263179T3 (es) * 1996-06-14 2006-12-01 Biocryst Pharmaceuticals Inc. Compuestos de clopentano sustituido como inhibidores de la neuraminidasa.
BR9813480A (pt) * 1997-12-17 2000-10-10 Biocryst Pharm Inc Compostos inibidores de neuraminidase de ciclopentano substituìdo, composição e métodos de inibição da neuraminidase do vìrus da influenza- e de tratamento de infecção por vìrus da influenza-
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
KR102323339B1 (ko) * 2006-02-13 2021-11-08 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료

Also Published As

Publication number Publication date
BRPI0707769A2 (pt) 2011-05-10
CA2642260A1 (en) 2007-08-23
KR102267754B1 (ko) 2021-06-23
KR102323339B1 (ko) 2021-11-08
KR20200143519A (ko) 2020-12-23
KR20210135632A (ko) 2021-11-15
HK1212250A1 (en) 2016-06-10
EP1986626A1 (en) 2008-11-05
KR101992585B9 (ko) 2022-09-20
KR102475176B1 (ko) 2022-12-07
KR102194015B1 (ko) 2020-12-22
MX2008010394A (es) 2009-01-12
WO2007095218A1 (en) 2007-08-23
KR20160129105A (ko) 2016-11-08
KR20080096829A (ko) 2008-11-03
AU2013216632A1 (en) 2013-08-29
AU2013216632B2 (en) 2016-09-01
KR20140132778A (ko) 2014-11-18
CA2642260C (en) 2016-08-09
KR101992585B1 (ko) 2019-06-25
JP2015180695A (ja) 2015-10-15
KR20180024027A (ko) 2018-03-07
KR20210076189A (ko) 2021-06-23
JP6073202B2 (ja) 2017-02-01
EA200870263A1 (ru) 2009-06-30
EA025483B1 (ru) 2016-12-30
KR20230003248A (ko) 2023-01-05
MY166063A (en) 2018-05-23
KR20190072681A (ko) 2019-06-25
AU2007215156A1 (en) 2007-08-23
MX2020002008A (es) 2020-07-13
JP2013256527A (ja) 2013-12-26
JP2009538822A (ja) 2009-11-12

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
BRPI0816116A2 (pt) Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
MX2010007936A (es) Anticuerpo anti-nr-10 y su uso.
EA201171367A1 (ru) Винилиндазолильные соединения
CY1115571T1 (el) Νεες ενωσεις και μεθοδοι για θεραπεια
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
DE60327618D1 (de) Gegen iap gerichtete antisense-nukleobasen und deren verwendungen
BRPI0813828A2 (pt) Compostos antimicrobianos, a síntese dos mesmos e o uso dos mesmos para o tratamento de infecções em mamíferos
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения